Furthermore, EFNA2 has been found to play an important role in angiogenesis and promoting epithelial-mesenchymal transformation in prostate cancer through in vitro and in vivo migration—and therefore a potential therapeutic target for prostate cancer (Zhao et al., 2021). This evidence concerns the gene EFNA2 and prostate carcinoma.